Determination of the Safety and Effectiveness of an Oral Rinse in the Reduction of Medication Associated Metallic Taste

NCT02992314 | Completed DMC FDA Device

• 1 other identifier: MQ-101-16
• Study Type: interventional
• Target: 52
• Locations: 1 country
• Sites: 1

Brief Summary

Patients taking chemotherapeutic agents often do not comply well with their dosing regiment since many of these medications cause a metallic taste in the mouth. The primary intent is to determine the effectiveness of the oral rinse in reducing the metallic taste in the mouth associated with various chemotherapeutic agents. This clinical study a randomized, double-blind, single-treatment, parallel design with a placebo as the control. The duration of the trial will be 1 month.

Conditions

Medication Associated Metallic Taste , Dysgeusia

Outcome Measures

Primary Outcomes (1)

• Relief of medication associated metallic taste

  Have patient complete a VAS ( visual analogue scale) scoring of the degree of metallic taste in the mouth as well as a VAS scoring of the amount of relief of the metallic taste..

  4 weeks

Secondary Outcomes (1)

• Safety evaluation of the test Oral Rinse

  4 Weeks

Study Arms (2)

Metaqil™ Oral Rinse

EXPERIMENTAL

In this arm the test article, Metaqil ™ oral rinse, a proprietary formulation of agents including Monk fruit extract, which can minimize the metallic taste in the mouth caused by the patient's medications. Subjects rinse twice a day with 10 mL of the oral rinse for 30 seconds for 30 days. They will note, in the daily oral hygiene diary, the date and time of brushing and rinsing.

Device: Metaqil™ Oral Rinse

Placebo Oral Rinse

PLACEBO COMPARATOR

This arm will use a placebo with out the active ingredients same way the experimental arm do.

Device: Placebo

Interventions

Metaqil™ Oral Rinse DEVICE

Metaqil™ is a proprietary formulation of GRAS ingradients

Metaqil™ Oral Rinse

Placebo DEVICE

Placebo formulation with out the active ingredients

Placebo Oral Rinse

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Subject has read, signed and received a copy of the Informed Consent and HIPAA authorization prior to study initiation.
• Subject is able to follow verbal and/or written instructions, perform oral hygiene procedures and return to the test facility for specified study examinations.
• Subject is between the ages of 18 and 75 years inclusive.
• Subject will not have professional cleaning during the 3-month trial.
• Subject has no history of allergy to personal care consumer products, or their ingredients, relevant to any ingredient in the test drug, as determined by the Principal Investigator.
• Subject has a minimum of 16 natural teeth and a complaint of moderate to severe medication associated metallic taste.
• Subject agrees to refrain from the use of any oral rinse, toothpaste or dentifrice other than the Colgate® Cavity Protection Fluoride toothpaste and study rinse provided on Visit 1 for the duration of the study.
• Subject agrees to refrain from the use of other oral care products not supplied by the study center
• Subject agrees to be compliant with study procedures.
• Females of childbearing potential agree to use an adequate method of birth control and agree to pregnancy testing at the first and second visit.

You may not qualify if:

• Subject has a condition that requires prophylactic antibiotics for dental examinations and treatments (e.g., has a history of valvular heart disease or a recently placed prosthetic joint).
• Subject has disqualifying acute or chronic medical illness as judged by the Principal Investigator.
• Subject is currently taking phenytoin, cyclosporin, nifedipine or any other drug that has been shown to cause gingival enlargement or affect the gingivae.
• Subject has taken antibiotics, steroids, or non-steroidal anti-inflammatory drugs (e.g., aspirin, ibuprofen) within one week prior to baseline examination. Subjects taking long-term aspirin (81 mg/day) may be included in the trial, but subjects taking a larger dose will be excluded. Subjects taking blood thinners such as Coumadin (warfarin), Lovenox, or Plavix will be excluded.
• Subject is pregnant (based on pregnancy result) or lactating.

Sponsors & Collaborators

• You First Services: lead

Study Sites (1)

Department of Periodontics and Endodontics,School of Dental Medicine, University at Buffalo, SUNY

Buffalo, New York, 14214, United States

Location

MeSH Terms

Conditions

Dysgeusia

Condition Hierarchy (Ancestors)

Taste Disorders; Sensation Disorders; Neurologic Manifestations; Nervous System Diseases; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR
• Purpose: SUPPORTIVE CARE
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 30, 2016
• First Posted: December 14, 2016
• Study Start: May 22, 2017
• Primary Completion: September 18, 2018
• Study Completion: December 31, 2018
• Last Updated: January 22, 2021

Record last verified: 2021-01

Locations

US (1)